Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer

  • Cardio-oncology (M Fradley, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Prostate cancer is a common hormone-sensitive malignancy, and androgen deprivation therapy (ADT) is a cornerstone of therapy in advanced disease. The most important and controversial of ADT side effects is cardiovascular (CV) toxicity. Prospective trials have demonstrated that ADT increases CV risk by lowering insulin sensitivity, causing dyslipidemia, and causing weight gain thus mimicking metabolic syndrome. Retrospective data suggests that ADT increases CV risk; however, data on cardiovascular mortality is equivocal. This discrepancy can be explained by study design limitations and selection bias inherent to post hoc analysis of trials not designed to study CV outcomes. Despite the adverse CV and metabolic sequelae of ADT, little data is available for optimal cardiac screening or management in these patients. The short-term CV risk is higher in patients who have had CV events in the year prior to starting ADT. A careful discussion of risk and benefit of ADT must take place with patients with pre-existing CV disease prior to initiating hormonal therapy. The duration of ADT must be considered. We recommend diligent pretherapy screening and optimization of cardiac risk factors and close surveillance especially within the first year of ADT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •  Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Satariano WA, Ragland KE, Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83(6):1180–8.

    Article  CAS  PubMed  Google Scholar 

  3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate *This investigation was aided by a grant from the Committee on Research in Problems of Sex, the National Research Council. J Urol. 2002;168(1):9–12. doi:10.1016/s0022-5347(05)64820-3.

  4. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J med. 1984;311(20):1281–6. doi:10.1056/nejm198411153112004.

    Article  Google Scholar 

  5. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Urologic Oncology: Seminars and Original Investigations. 2003;21(4):309–10. doi:10.1016/s1078-1439(03)00087-5.

    Article  Google Scholar 

  6. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet Oncology. 2006;7(6):472–9. doi:10.1016/s1470-2045(06)70700-8.

    Article  CAS  PubMed  Google Scholar 

  7. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National Practice Patterns and time trends in androgen ablation for localized prostate cancer. JNCI Journal of the National Cancer Institute. 2003;95(13):981–9. doi:10.1093/jnci/95.13.981.

    Article  PubMed  Google Scholar 

  8. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology. 2010;11(11):1066–73. doi:10.1016/s1470-2045(10)70223-0.

    Article  CAS  PubMed  Google Scholar 

  9. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol. 2003;21(21):3972–8.

    Article  CAS  PubMed  Google Scholar 

  10. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–90.

    Article  CAS  PubMed  Google Scholar 

  11. Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. International Journal of Radiation Oncology* Biology* Physics. 2012;83(5):1473–9.

  12. Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D’Amico AV, et al. Weighing risk of cardiovascular mortality against potential benefit of hormonal therapy in intermediate-risk prostate cancer. J Natl Cancer Inst. 2017;109(6):djw281.

    Article  PubMed  Google Scholar 

  13. Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D’amico AV. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer. 2015;121(16):2713–9.

    Article  CAS  PubMed  Google Scholar 

  14. Levine GN, D’Amico, AV, Berger P, Clark PE, Eckel RH, Keating NL et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. <span class="subtitle">A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: <em>Endorsed by the American Society for Radiation Oncology</em></span>. 2010;121(6):833–40. doi:10.1161/circulationaha.109.192695.

  15. Eggener S. Commentary on ‚ÄúIntermittent versus continuous androgen deprivation in prostate cancer.‚Äù Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. Urologic Oncology: Seminars and Original Investigations. 2014;32(6):936–7. doi:10.1016/j.urolonc.2014.01.009.

  16. Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients. 2014;6(10):4491–519. doi:10.3390/nu6104491.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–29.

    Article  CAS  PubMed  Google Scholar 

  18. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Current Opinion in Supportive and Palliative Care. 2010;4(3):147–52. doi:10.1097/spc.0b013e32833bd913.

    Article  PubMed  Google Scholar 

  19. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of Clinical Endocrinology & Metabolism. 2002;87(2):599–603. doi:10.1210/jcem.87.2.8299.

    Article  CAS  Google Scholar 

  20. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. The Journal of Clinical Endocrinology &amp. Metabolism. 2001;86(9):4261–7. doi:10.1210/jcem.86.9.7851.

    CAS  Google Scholar 

  21. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39(12):1314–9. doi:10.1016/0026-0495(90)90190-n.

    Article  CAS  PubMed  Google Scholar 

  22. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–7. doi:10.1016/s0022-5347(05)64985-3.

    Article  PubMed  Google Scholar 

  23. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63(4):742–5. doi:10.1016/j.urology.2003.10.063.

    Article  PubMed  Google Scholar 

  24. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. The Journal of Clinical Endocrinology & Metabolism. 2006;91(4):1305–8. doi:10.1210/jc.2005-2507.

    Article  CAS  Google Scholar 

  25. Keating NL. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56. doi:10.1200/jco.2006.06.2497.

    Article  CAS  PubMed  Google Scholar 

  26. Keating NL, Liu P-H, O’Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24. doi:10.1016/j.eururo.2013.02.023.

    Article  CAS  PubMed  Google Scholar 

  27. Tsai H-T, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Yood MU, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015;193(6):1956–62.

    Article  CAS  PubMed  Google Scholar 

  28. Braga-Basaria M. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83. doi:10.1200/jco.2006.05.9741.

    Article  PubMed  Google Scholar 

  29. Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One. 2015;10(3):e0117344.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer. 2008;112(10):2188–94. doi:10.1002/cncr.23440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318–22. doi:10.1016/j.urology.2007.08.035.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gandaglia G, Sun M, Briganti A, Karakiewicz PI. Reply to E. David Crawford and Bo-Eric Persson’s Letter to the Editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. doi:10.1016/j.eururo.2014.01.026. European Urology. 2014;66(2):e36-e7. doi:10.1016/j.eururo.2014.03.043.

  33. Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. Jama. 2013;310(3):289. doi:10.1001/jama.2013.8638.

    Article  CAS  PubMed  Google Scholar 

  34. Dockery F, Bulpitt CJ, Donaldson M, Fernandez S, Rajkumar C. The relationship between androgens and arterial stiffness in older men. J am Geriatr Soc. 2003;51(11):1627–32.

    Article  PubMed  Google Scholar 

  35. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410–5.

    Article  CAS  PubMed  Google Scholar 

  36. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–9.

    Article  CAS  PubMed  Google Scholar 

  37. Danesh J, Lewington S, Thompson SG, Lowe G, Collins R, Kostis J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Jama. 2005;294(14):1799–809.

    CAS  PubMed  Google Scholar 

  38. Ziaran S, Goncalves FM, Breza J. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol. 2013;31(2):289–92.

    Article  CAS  PubMed  Google Scholar 

  39. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30(7):1282–92.

    Article  CAS  PubMed  Google Scholar 

  40. Li S, Li X, Li J, Deng X, Li Y, Cong Y. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb res. 2007;121(1):127–34.

    Article  CAS  PubMed  Google Scholar 

  41. Campelo AE, Cutini PH, Massheimer VL. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012;213(1):77–87.

    Article  CAS  PubMed  Google Scholar 

  42. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101(5):618–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Webb CM, McNeill JG, Hayward CS, De Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690–6.

    Article  CAS  PubMed  Google Scholar 

  44. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation. 2000;102(16):1906–11.

    Article  CAS  PubMed  Google Scholar 

  45. Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E et al. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. American journal of epidemiology. 2011:kwr172.

  46. Vaidya D, Golden SH, Haq N, Heckbert SR, Liu K, Ouyang P. Association of sex Hormones with carotid artery distensibility in men and postmenopausal women: multi-ethnic study of atherosclerosis. Hypertension. 2015;65(5):1020–5. doi:10.1161/hypertensionaha.114.04826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Collaboration ERF. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J med. 2012;2012(367):1310–20.

    Article  Google Scholar 

  48. Glueck CJ, Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism. 2014;63(8):989–94. doi:10.1016/j.metabol.2014.05.005.

    Article  CAS  PubMed  Google Scholar 

  49. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Jama. 2011;306(21):2359–66.

    Article  CAS  PubMed  Google Scholar 

  50. •• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–96. This meta-analysis included eight observational studies and result showed association between ADT and increased risk of CVD

    Article  PubMed  Google Scholar 

  51. • Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73. This study analyzed data from six phase III clinical trials and noted that in patients with preexisting cardiovascular disease, the risk of cardiac events within 1 year of initiating ADT was significantly lower with GnRH antagonist in comparison with GnRH agonists

    Article  CAS  PubMed  Google Scholar 

  52. •• O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51. This study showed increased incidence of CVD in patient receiving ADT and orchiectomy especially the first 6 months of treatment

    Article  PubMed  Google Scholar 

  53. • Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, et al. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014;114(6b):E82–E9. This study showed that GnRH agonists, but not orchiectomy, are associated with a significantly increased risk of CAD, AMI, and, especially, SCD in patients with non-metastatic prostate cancer. Alternative forms of ADT should be considered in patients at higher risk of CV events

    Article  CAS  PubMed  Google Scholar 

  54. • Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9(9):e107516. doi:10.1371/journal.pone.0107516. This study showed that ADT is associated with both CVD and CVM. Particularly, GnRH alone and GnRH plus AA can significantly increase the incidence of cardiovascular events in patients with PCa

    Article  PubMed  PubMed Central  Google Scholar 

  55. •• Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, et al. Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOsIng Treatment for Prostate canCEr (CHOICE) study. Urology. 2016;96:165–70. doi:10.1016/j.urology.2016.06.024. This study showed that about one-third of patients with prostate cancer received inappropriate ADT are at greater risk of CVD and osteoporosis

    Article  PubMed  Google Scholar 

  56. •• Wallis CJ, Mahar AL, Satkunasivam R, Herschorn S, Kodama RT, Lee Y, et al. Cardiovascular and skeletal-related events following localized prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. Urology. 2016;97:145–52. doi:10.1016/j.urology.2016.08.002. This study showed use of ADT for patients with localized disease undergoing radiotherapy had higher prevalence of cardiovascular and fracture; Risks vs benefits should be discussed of treatment for localized prostate cancer

    Article  PubMed  Google Scholar 

  57. •• Kohutek ZA, Weg ES, Pei X, Shi W, Zhang Z, Kollmeier MA, et al. Long-term impact of androgen-deprivation therapy on cardiovascular morbidity after radiotherapy for clinically localized prostate cancer. Urology. 2016;87:146–52. doi:10.1016/j.urology.2015.08.029. This study showed an higher incidence of cardiovascular events in patients receiving ADT in association with radiotherapy

    Article  PubMed  Google Scholar 

  58. •• Voog JC, Paulus R, Shipley WU, Smith MR, DG MG, Jones CU, et al. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08. Eur Urol. 2016;69(2):204–10. doi:10.1016/j.eururo.2015.08.027. This study supports the hypothesis that ADT does not increase CVM risk in men with clinically localized PCa treated with short-course GnRH agonist therapy

    Article  CAS  PubMed  Google Scholar 

  59. Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(Suppl 5):3–13. doi:10.1111/bju.12964.

    Article  PubMed  Google Scholar 

  60. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncology. 2015;1(9):1261–9.

    Article  PubMed  Google Scholar 

  61. da Silva FEC, Bono AV, Whelan P, Brausi M, Queimadelos AM, Martin JAP, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–77.

    Article  Google Scholar 

  62. da Silva FC, da Silva FMC, Gonçalves F, Santos A, Kliment J, Whelan P, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 2014;66(2):232–9.

    Article  CAS  Google Scholar 

  63. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncology. 2016;2(4):453–61.

    Article  PubMed  PubMed Central  Google Scholar 

  64. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA - Journal of the American Medical Association. 2008;299(3):289–95. doi:10.1001/jama.299.3.289.

    PubMed  Google Scholar 

  65. •• Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic dis. 2016;19(4):333–9. doi:10.1038/pcan.2016.35. This study compared intermittent vs continuous ADT in prostate cancer patients. It showed no significant difference in the risk of cardiovascular and thromboembolic events

    Article  CAS  PubMed  Google Scholar 

  66. Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology. 2013;1(4):583–9. doi:10.1111/j.2047-2927.2013.00093.x.

    Article  CAS  PubMed  Google Scholar 

  67. Jones LW, Alfano CM. Exercise-oncology research: past, present, and future. Acta Oncol. 2013;52(2):195–215.

    Article  PubMed  Google Scholar 

  68. Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–66.

    Article  PubMed  Google Scholar 

  69. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–46. doi:10.1200/jco.2013.49.5523.

    Article  PubMed  Google Scholar 

  70. •• Galvao DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65(5):856–64. doi:10.1016/j.eururo.2013.09.041. In this study supervised exercise training in long-term PCa survivors was more effective than physical activity educational material for increasing cardiorespiratory fitness, physical function, muscle strength, and self-reported physical functioning at 6 months. Benefits were maintained in the long term follow up to one year

    Article  PubMed  Google Scholar 

  71. •• Li X-X, Zhang Y-G, Wang D, Chen Y-F, Shan Y-H. Preventive effects of aspirin on cardiovascular complications in prostate cancer cases after endocrinotherapy. Asian Pac J Cancer Prev. 2015;16(12):4909–13. doi:10.7314/apjcp.2015.16.12.4909. This study showed that cardiovascular complications of ADT can be prevented by aspirin

    Article  PubMed  Google Scholar 

  72. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). Jama. 2011;306(14):1549–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY, 10065, USA

    Dipti Gupta MD MPH, Chadi Salmane MD, Susan Slovin MD, PhD & Richard M. Steingart MD

  2. Weill Cornell Medical College, New York, NY, USA

    Dipti Gupta MD MPH & Richard M. Steingart MD

Authors
  1. Dipti Gupta MD MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chadi Salmane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan Slovin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard M. Steingart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dipti Gupta MD MPH.

Ethics declarations

Disclosures

None

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, D., Salmane, C., Slovin, S. et al. Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Curr Treat Options Cardio Med 19, 61 (2017). https://doi.org/10.1007/s11936-017-0563-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-017-0563-1

Keywords

Search

Navigation